Hormone Therapy News

The FDA today approved prasterone for treatment of moderate to severe pain during sexual intercourse, a symptom of vulvar and vaginal atrophy, in postmenopausal women, according to an FDA press release.

Postmenopausal women who discontinue hormone therapy experience a loss of protection against hip fracture, but there is no “rebound increase” in risks for hip fracture or total fracture vs. those assigned a placebo, according to an analysis of the Women’s Health Initiative.

Young adults with Prader-Willi syndrome who continued previous growth hormone therapy for 1 year after attaining adult height saw no adverse effects on metabolic parameters, according to findings from a randomized crossover study.

Men assigned norethisterone enanthate with testosterone undecanoate for up to 26 weeks effectively achieved suppression of spermatogenesis, and the effect was successfully reversed in most men, international study data show.

The FDA approved classwide labeling changes for all prescription testosterone products to alert prescribers to the abuse potential and serious adverse outcomes related to testosterone and anabolic androgenic steroid use.

Women with polycystic ovary syndrome assigned the polyphenol resveratrol for 3 months saw a marked reduction in testosterone and dehydroepiandrosterone sulfate vs. those assigned a placebo, according to findings from a randomized trial.

Use of the 3-year etonogestrel-releasing subdermal implant for 5 years was effective in preventing pregnancy, and adverse effects were similar to those that occur with the 5-year levonorgestrel implant, study data show.

Transgender women may be more likely than transgender men or the general population to quit or decrease smoking when initiating hormone therapy, study data show.

Physical and sexual quality of life may substantially decrease in men with prostate cancer undergoing androgen deprivation therapy compared with those not using such therapy, study data show.

Healthy, premenopausal women exposed to a temporary decline in estradiol were more likely to experience mild depressive symptoms if they perceived nighttime hot flashes along with sleep disruption, according to study results.